103 related articles for article (PubMed ID: 2386894)
1. A phase II study of pirarubicin in malignant pleural mesothelioma.
Kaukel E; Koschel G; Gatzemeyer U; Salewski E
Cancer; 1990 Aug; 66(4):651-4. PubMed ID: 2386894
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pirarubicin in metastatic breast cancer.
Kleeberg UR; Reichel L; Wander HE; Beyer JH; Essers U; Fiebig HH; Salewski E; Greifenberg B; Edler L
Onkologie; 1990 Jun; 13(3):175-9. PubMed ID: 2204003
[TBL] [Abstract][Full Text] [Related]
3. [A diffuse, pleural, malignant mesothelioma kept in long remission by chemotherapy combining pirarubicin and cisplatin].
Niki Y; Soga T; Nishimura A; Kato M; Hamada M; Kanamaru M
Gan No Rinsho; 1990 Nov; 36(14):2463-7. PubMed ID: 2250368
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Dirix LY; van Meerbeeck J; Schrijvers D; Corthouts B; Prové A; van Marck E; Vermeire P; van Oosterom AT
Ann Oncol; 1994 Sep; 5(7):653-5. PubMed ID: 7993844
[TBL] [Abstract][Full Text] [Related]
5. Activity of pirarubicin (4'-0-tetrahydropyranyladriamycin) in malignant mesothelioma.
Sridhar KS; Hussein AM; Feun LG; Zubrod CG
Cancer; 1989 Mar; 63(6):1084-91. PubMed ID: 2917312
[TBL] [Abstract][Full Text] [Related]
6. Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.
Scheithauer W; Samonigg H; Depisch D; Schüller J; Hausmaninger H; Wiegele J; Zielinsky C; Stöger H; Haider K; Preis P
Invest New Drugs; 1990 May; 8(2):207-10. PubMed ID: 2384308
[TBL] [Abstract][Full Text] [Related]
7. Caelyx in malignant mesothelioma: a phase II EORTC study.
Baas P; van Meerbeeck J; Groen H; Schouwink H; Burgers S; Daamen S; Giaccone G
Ann Oncol; 2000 Jun; 11(6):697-700. PubMed ID: 10942058
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
Pinto C; Marino A; Guaraldi M; Melotti B; Piana E; Martoni A; Pannuti F
Am J Clin Oncol; 2001 Apr; 24(2):143-7. PubMed ID: 11319288
[TBL] [Abstract][Full Text] [Related]
9. Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.
Dittrich C; Baur M; Mader R; Schlappack O; Dudczak R; Leitha T; Lenzhofer R; Hoffmann S; Vieder L; Heberle U
Am J Clin Oncol; 1990; 13 Suppl 1():S29-39. PubMed ID: 1963274
[TBL] [Abstract][Full Text] [Related]
10. Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
Hillerdal G; Sorensen JB; Sundström S; Vikström A; Hjerpe A
Clin Respir J; 2008 Apr; 2(2):80-5. PubMed ID: 20298311
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of detorubicin in malignant mesothelioma.
Colbert N; Vannetzel JM; Izrael V; Schlienger M; Milleron B; Blanchon F; Herman D; Akoun G; Roland J; Chatelet F
Cancer; 1985 Nov; 56(9):2170-4. PubMed ID: 3902205
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide in malignant mesothelioma: a phase II study.
Andersen MK; Krarup-Hansen A; Mårtensson G; Winther-Nielsen H; Thylen A; Damgaard K; Olling S; Wallin J
Lung Cancer; 1999 Apr; 24(1):39-43. PubMed ID: 10403693
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
[TBL] [Abstract][Full Text] [Related]
17. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
[TBL] [Abstract][Full Text] [Related]
18. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
19. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
[TBL] [Abstract][Full Text] [Related]
20. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]